Cargando…
Enhanced nanoparticle delivery exploiting tumour-responsive formulations
Nanoparticles can be used as drug carriers, contrast agents and radiosensitisers for the treatment of cancer. Nanoparticles can either passively accumulate within tumour sites, or be conjugated with targeting ligands to actively enable tumour deposition. With respect to passive accumulation, particl...
Autores principales: | Bennie, Lindsey A., McCarthy, Helen O., Coulter, Jonathan A. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Vienna
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6276285/ https://www.ncbi.nlm.nih.gov/pubmed/30595759 http://dx.doi.org/10.1186/s12645-018-0044-6 |
Ejemplares similares
-
Formulating RALA/Au nanocomplexes to enhance nanoparticle internalisation efficiency, sensitising prostate tumour models to radiation treatment
por: Bennie, Lindsey A., et al.
Publicado: (2021) -
Exploiting the anticancer effects of a nitrogen bisphosphonate nanomedicine for glioblastoma multiforme
por: Jena, Lynn N, et al.
Publicado: (2021) -
Development of a Spray-Dried Formulation of Peptide-DNA Nanoparticles into a Dry Powder for Pulmonary Delivery Using Factorial Design
por: Munir, Miftakul, et al.
Publicado: (2022) -
Exploiting Current Understanding of Hypoxia Mediated Tumour Progression for Nanotherapeutic Development
por: Feng, Jie, et al.
Publicado: (2019) -
Exploitation of High Tumour GSH Levels for Targeted siRNA Delivery in Rhabdomyosarcoma Cells
por: Duan, Chengchen, et al.
Publicado: (2022)